Actimed Therapeutics

The company's lead product is S-pindolol benzoate (ACM-001.1), a small molecule described as an Anabolic, Catabolic Transforming Agent (ACTA). It is being developed to treat cancer-related cachexia, a wasting disease that affects a high percentage of cancer patients and is responsible for a significant number of cancer deaths. S-pindolol has a multi-modal action, aiming to reduce weight loss (catabolism), increase muscle mass (anabolism), and improve appetite and fatigue. The company is preparing for Phase 2b/3 clinical trials (the IMPACT programme) for S-pindolol in patients with Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC). Additionally, Actimed is exploring the use of S-pindolol to preserve muscle mass in obese patients undergoing treatment with GLP-1 receptor agonists.

Actimed's second asset is S-oxprenolol, which is being developed for treating muscle wasting associated with amyotrophic lateral sclerosis (ALS). The company has licensed the global rights for S-oxprenolol's development in indications outside of ALS, including cancer cachexia, to the U.S.-based Faraday Pharmaceuticals, while retaining the rights for ALS. Based in London, UK, Actimed Therapeutics operates on a venture capital-backed business model, raising funds through financing rounds to advance its clinical pipeline. The company has successfully closed multiple seed and Series A funding rounds, with notable investment from Mankind Pharma.